

Dr. Forde is a medical oncologist who treats patients with lung cancer, mesothelioma, and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Co-Director of the Division of Upper Aerodigestive Malignancies in the Department of Oncology at Johns Hopkins and directs the multidisciplinary Thoracic Oncology Clinical Research Program.

He has led development of a translational research program focused on the immuno-oncology of upper aerodigestive malignancies. Dr. Forde's research examines the role of immunotherapy for mesothelioma and lung cancer and his investigator-initiated research forms the basis for several ongoing phase 3 trials. In 2022, his work over several years, culminated in publication of the CheckMate 816 trial in the New England Journal of Medicine and led to the first approval of neoadjuvant chemo-immunotherapy for the treatment of surgically operable lung cancer.